Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial...
Company Anticipates Significant Sequential Growth in Quarterly Revenues Beginning in Q3 2024 and Beyond Reports Pharmaloz Growth Acceleration Has Begun...
HALIFAX, NS / ACCESSWIRE / August 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces it will conduct full clinical...
Designed To Support Patient Engagement And Improve Access To Medication Information WOBURN, Mass., Aug. 13, 2024 /PRNewswire/ -- MedAdvisor Solutions, the...
RADIAN's Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on...
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidineCompany anticipates new data...
The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) --...
Secure Bluetooth® Connectivity Allows Continuous, Accurate Wrist-based Measurements to be Seamlessly Relayed to Caregivers via the Masimo Secure Health Data...
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / August 8, 2024...
CHICAGO, IL / ACCESSWIRE / August 8, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...
SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in...
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before...
This collaboration provides career opportunities for critical care professionals by creating connections with employers seeking these highly sought-after and specialized...
Net income for the quarter ended June 30, 2024 was $1.6 million or $0.15 per diluted share, compared to net...
SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an...
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a...
MURFREESBORO, TN / ACCESSWIRE / August 6, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that it will pay...
Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON and ROLLE, Switzerland,...